The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Open accessAbstract
Key Points: Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citation
Cited by
Sorted by citations
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationMateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationXu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., Xu, J., Zhuang, Y., Zhang, W., Weng, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 393
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
Self-citationTreatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J. R., Ismaila, N., Cheung, M. C., Costello, C. L., Dhodapkar, M. V., Kumar, S. K., Lacy, M. Q., Lipe, B. C., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 344
Moreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 290
Self-citationFacon, T. T. F., Dimopoulos, M. A., Meuleman, N., Belch, A., Mohty, M., Chen, W., Kım, K., Zamagni, E., Rodríguez‐Otero, P., Renwick, W. E. P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0539-0 · Cited by 240
Self-citationTuresson, I., Björkholm, M., Blimark, C. H., Kristinsson, S. Y., Vélez, R., & Landgren, O. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13083 · Cited by 188
Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00236-3 · Cited by 178
Facon, T. T. F., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M. A., Hájek, R., Pour, L., Jurczyszyn, A. J., Qiu, L., Klippel, Z. K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874396 · Cited by 129
Self-citationBiology and therapy of multiple myeloma
Joshua, D., Bryant, C. E., Dix, C. H. K., Gibson, J., & Ho, P. J. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50129 · Cited by 128
Recurrent aphthous ulceration: a review of potential causes and novel treatments
Saikaly, S. K., Saikaly, T. S., & Saikaly, L. E. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1422079 · Cited by 124
Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0273-x · Cited by 116
Self-citationCook, G., Royle, K., Pawlyn, C., Hockaday, A., Shah, V., Kaiser, M., Brown, S., Gregory, W. M., Child, J. A., Davies, F. E., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30220-5 · Cited by 113
Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 108
Self-citationFacon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood · doi:10.1182/blood.2020008787 · Cited by 104
Self-citationRepurposing old drugs to fight multidrug resistant cancers
Dinić, J., Efferth, T., García‐Sosa, A. T., Grahovac, J., Padrón, J. M., Pajeva, I. K., Rizzolio, F., Saponara, S., Spengler, G., & Tsakovska, I. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100713 · Cited by 102
Duan, D., Wang, K., Cheng, W., Feng, D., Liu, Y., He, Q., Xu, X., Wang, C., Zhao, S., Lv, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609421 · Cited by 90
Dimopoulos, M. A., Špıčka, I., Quach, H., Oriol, A., Hájek, R., Garg, M. K., Beksaç, M., Bringhen, S., Katodritou, E., Chng, W. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02060 · Cited by 81
Self-citationSecond primary malignancies in multiple myeloma: A review
Poh, C., Keegan, T. H. M., & Rosenberg, A. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100757 · Cited by 75
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, J. K., Kubicki, T., Raje, N. S., Vij, R., Reece, D. E., Berdeja, J. G., Derman, B. A., Rosenbaum, C. A., Richardson, P. G. G., Gurbuxani, S. K., et al. (2020) · Blood · doi:10.1182/blood.2020007522 · Cited by 74
Current approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 76
Dumontet, C., Hulin, C., Dimopoulos, M. A., Belch, A. R., Dispenzieri, A. A., Ludwig, H., Rodon, P., Droogenbroeck, J. V., Qiu, L., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0133-x · Cited by 74
Self-citationHow I treat multiple myeloma in geriatric patients
Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 72
Self-citationTreatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationEisfeld, C., Kajüter, H., Möller, L., Wellmann, I., Shumilov, E., & Stang, A. (2023) · BMC Cancer · doi:10.1186/s12885-023-10787-5 · Cited by 61
Ixazomib for the treatment of multiple myeloma
Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 61
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 59
Perspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 65
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 62
Current Treatment Strategies for Multiple Myeloma
Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 56
Insights on Multiple Myeloma Treatment Strategies
Mateos, M., Ludwig, H., Bazarbachi, A. A., Beksaç, M., Bladé, J., Boccadoro, M., Cavo, M., Delforge, M., Dimopoulos, M. A., Facon, T. T. F., et al. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000163 · Cited by 51
Self-citationApproach to the Older Adult With Multiple Myeloma
Mina, R., Bringhen, S., Wildes, T. M., Zweegman, S., & Rosko, A. E. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239067 · Cited by 51
Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R. A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0384-1 · Cited by 50
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00103-x · Cited by 48
Self-citationSaleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 50
Chakraborty, R., Riaz, I. B., Malik, S. U., Marneni, N., Garcia, A. M., Anwer, F., Khorana, A. A., Rajkumar, S. V., Kumar, S. K., Murad, M. H., et al. (2020) · Cancer · doi:10.1002/cncr.32682 · Cited by 48
Argueta, C. E., Kashyap, T., Klebanov, B., Unger, T. J., Guo, C., Harrington, S., Baloglu, E., Lee, M., Senapedis, W. T., Shacham, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25368 · Cited by 48
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies, F. E., Pawlyn, C., Usmani, S. Z., Miguel, J. F. S., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0205 · Cited by 45
Self-citationChari, A., Richardson, P. G. G., Romanus, D., Dimopoulos, M. A., Sonneveld, P., Terpos, E., Hájek, R., Raju, A., Palumbo, A. P., Cain, L. E., et al. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1729734 · Cited by 43
Self-citationBringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 42
Hernández‐Rivas, J., Ríos, R., Encinas, C., Alonso, R., & Lahuerta, J. J. (2022) · Biomarker Research · doi:10.1186/s40364-021-00344-2 · Cited by 40
Deshantri, A. K., Fens, M. H. A. M., Ruiter, R. W. J., Metselaar, J. M., Storm, G., van Bloois, L., Varela-Moreira, A., Mandhane, S. N., Mutis, T., Martens, A. C., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.028 · Cited by 39
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Alonso, R., Cedena, M., Wong, S. W. K., Shah, N. D., Ríos, R., Moraleda, J. M., López‐Jiménez, J., García, C., Bahri, N., Valeri, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001508 · Cited by 38
A comprehensive approach to therapy of haematological malignancies in older patients
Córdoba, R., Eyre, T. A., Klepin, H. D., Wildes, T. M., & Goede, V. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00241-6 · Cited by 38
Induction Therapy for Newly Diagnosed Multiple Myeloma
Paul, B. A., Lipe, B. C., Ocio, E. M., & Usmani, S. Z. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238527 · Cited by 36
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
D’Agostino, M., Bertamini, L., Oliva, S., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers11122015 · Cited by 35
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
Bobin, A., Liuu, É., Moya, N., Gruchet, C., Sabirou, F., Lévy, A., Gardeney, H., Nsiala, L., Cailly, L., Guidez, S., et al. (2020) · Cancers · doi:10.3390/cancers12102885 · Cited by 36
Self-citationTreatment horizon in multiple myeloma
Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 37
Piechotta, V., Jakob, T., Langer, P. H., Monsef, I., Scheid, C., Estcourt, L. J., Ocheni, S., Theurich, S., Kuhr, K., Scheckel, B., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013487 · Cited by 35
Askeland, F. B., Haukås, E., Slørdahl, T. S., Klostergaard, A., Alexandersen, T., Osnes, L., Lysén, A., Abdollahi, P., Nielsen, L. K., Hermansen, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00347-8 · Cited by 34
Kaweme, N. M., Changwe, G. J., & Zhou, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.612696 · Cited by 35
Dimopoulos, M. A., Grosicki, S., Wiktor-Jędrzejczak, W., Nahi, H., Gruber, A., Hansson, M., Gupta, N., Byrne, C., Labotka, R., Teng, Z., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.011 · Cited by 33
Self-citationLenalidomide use in multiple myeloma (Review)
Zhang, C.-W., Wang, Y., & Ge, X. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2705 · Cited by 34
Cavo, M., Terpos, E., Bargay, J., Einsele, H., Cavet, J., Greil, R., & de Wit, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1437345 · Cited by 32
Self-citationKiss, S., Gede, N., Soós, A., Hegyi, P. J., Nagy, B., Imrei, M., Czibere, B., Farkas, N., Hanák, L., Szakács, Z., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103504 · Cited by 31
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 30
Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials
Mohyuddin, G. R., Koehn, K., Abdallah, A.-O. A., Goodman, A. M., & Prasad, V. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8084 · Cited by 30
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 31
Merz, M., Dechow, T. N., Scheytt, M., Schmidt, C., Hackanson, B., & Knop, S. T. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04023-4 · Cited by 29
Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2021) · Cancers · doi:10.3390/cancers13184666 · Cited by 31
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, C., Hernández‐Rivas, J., Oriol, A., Rosiñol, L., Blanchard, M. J., Bellón, J. M., García‐Sánz, R., de la Rubia, J., de la Guía, A. L., Ubieto, A. J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00652-2 · Cited by 29
Self-citationPuig, N., Hernández, M. T., Rosiñol, L., González, E., de Arriba, F., Oriol, A., González‐Calle, V., Escalante, F., de la Rubia, J., Gironella, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00490-8 · Cited by 28
Self-citationMitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
Nair, R., Gupta, P., & Shanmugam, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000106 · Cited by 29
Moore, K. L. F., Turesson, I., Genell, A., Klausen, T. W., Knut‐Bojanowska, D., Redder, L., Sverrisdottir, I. S., Thorsen, J., Vangsted, A. J., & Blimark, C. H. (2022) · Haematologica · doi:10.3324/haematol.2021.280424 · Cited by 28
Avet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 26
Self-citationCytokine-induced killer cells: new insights for therapy of hematologic malignancies
Sevari, F. G., Mehdizadeh, A., Abbasi, K., Hejazian, S. S., & Raeisi, M. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03869-z · Cited by 25
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma
Binder, M., Rajkumar, S. V., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dispenzieri, A. A., Hwa, Y. L., Fonder, A. L., Hobbs, M., Hayman, S. R., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25365 · Cited by 25
Self-citationFrontline therapy for newly diagnosed patients with multiple myeloma
Jung, S., Jo, J., Song, G., Ahn, S., Yang, D., Ahn, J., Kim, H., & Lee, J. (2020) · Blood Research · doi:10.5045/br.2020.s007 · Cited by 25
Self-citationProgression with clinical features is associated with worse subsequent survival in multiple myeloma
Chakraborty, R., Liu, H. D., Rybicki, L. A., Tomer, J., Khouri, J., Dean, R. M., Faiman, B. M., Kalaycio, M. E., Samaras, C. J., Majhail, N. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25415 · Cited by 24
Mian, H. S., Mian, O., Rochwerg, B. N., Foley, R., & Wildes, T. M. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.014 · Cited by 24
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
Martino, M. V., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P. F., et al. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1634541 · Cited by 24
Maclachlan, K. H., Came, N. A., Diamond, B. T., Roshal, M., Ho, C., Thoren, K. L., Mayerhoefer, M. E., Landgren, O., & Harrison, S. J. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.003 · Cited by 24
McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 26
Bergin, K., Wellard, C. J., Moore, E., McQuilten, Z., Blacklock, H. A., Harrison, S. J., Ho, P. J., King, T., Quach, H., Mollee, P. N., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.01.016 · Cited by 23
Wildes, T. M., & Anderson, K. C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.88 · Cited by 21
Self-citationRaje, N. S., Mateos, M., Iida, S., & Reece, D. E. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00804-y · Cited by 20
How I treat elderly patients with plasma cell dyscrasias
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20
Self-citationFiala, M. A., Foley, N. C., Zweegman, S., Vij, R., & Wildes, T. M. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.03.005 · Cited by 20
Sim, S., Kalff, A., Tuch, G., Mollee, P. N., Ho, P. J., Harrison, S. J., Gibbs, S. D., Prince, H. M., Spencer, A. G., Joshua, D., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16049 · Cited by 19
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
Chacon, A., Leleu, X., & Bobin, A. (2023) · Cancers · doi:10.3390/cancers15071929 · Cited by 16
Self-citationDimopoulos, M. A., Niesvizky, R., Weisel, K. C., Siegel, D. S. D., Hájek, R., Mateos, M., Cavo, M., Huang, M., Zahlten‐Kumeli, A., & Moreau, P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0300-y · Cited by 19
Self-citationMiguel, J. F. S., Gutierrez, M. A. E., Špıčka, I., Mateos, M., Song, K., Craig, M., Bladé, J., Hájek, R., Chen, C. I., Bacco, A. D., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185991 · Cited by 19
Self-citationCosta, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F. F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220657 · Cited by 18
Terebelo, H. R., Abonour, R., Gasparetto, C., TOOMEY, K. E., Durie, B. G. M., Hardin, J. W., Jagannath, S., Wagner, L. I., Narang, M., Flick, E. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16139 · Cited by 19
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 17
Leleu, X. P., Beksaç, M., Chou, T., Dimopoulos, M. A., Yoon, S., Prince, H. M., Pour, L., Shelekhova, T. V., Chari, A., Khurana, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1832672 · Cited by 17
Self-citationGrant, S. J., Mian, H. S., Giri, S., Boutin, M., Dottorini, L., Neuendorff, N. R., Krok‐Schoen, J. L., Nikita, N., Rosko, A. E., Wildes, T. M., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.12.001 · Cited by 17
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 17
Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Cancers · doi:10.3390/cancers14246216 · Cited by 17
Self-citationTreatment of older adult or frail patients with multiple myeloma
Grant, S. J., Freeman, C. L. L., & Rosko, A. E. (2021) · Hematology · doi:10.1182/hematology.2021000231 · Cited by 16
Bonello, F., Boccadoro, M., & Larocca, A. (2020) · Cancers · doi:10.3390/cancers12113106 · Cited by 16
D’Agostino, M., Paoli, L. D., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.008 · Cited by 16
Mizuno, S., Kawamura, K., Hanamura, I., Sunami, K., Mori, T., Nakamura, F., Iida, S., Nakazawa, H., Makita, M., Kako, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0478-4 · Cited by 16
Chan, H. S. H., Chai, K., Shih, S., Lewsey, R., Chen, K. Y., McDiarmid, B., Jackson, S., & Simpson, D. (2019) · British Journal of Haematology · doi:10.1111/bjh.16095 · Cited by 15
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders
Chung, A., & Liedtke, M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.003 · Cited by 15
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
Bashir, Q., Chamoun, K., Milton, D. R., Khan, M., Ahmed, S., Mehta, R. S., Popat, U., Kebriaei, P., Nieto, Y. L., Oran, B., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633633 · Cited by 15
Botta, C., Gigliotta, E., Paiva, B., Anselmo, R., Santoro, M., Rodríguez‐Otero, P., Carlisi, M., Conticello, C., Romano, A., Solimando, A. G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3041 · Cited by 15
Metadata
- Authors
- Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J. D., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., De La Rubia, J., White, D., Binder, D., Lu, J., Anderson, K. C., Moreau, P., Attal, M., Perrot, A., Arnulf, B., Qiu, L., Roussel, M., Boyle, E., Manier, S., Mohty, M., Avet-Loiseau, H., Leleu, X., Ervin-Haynes, A., Chen, G., Houck, V., Benboubker, L., & Hulin, C.
- Affiliations
- Hôpital Claude Huriez (FR)
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- Cross Cancer Institute (CA)
- Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Department of Hematology, University Hospital, La Roche Sur Yon, France;
- Universitair Ziekenhuis Leuven (BE)
- National Health Service (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Hospital Dr. Peset, Valencia, Spain;
- Queen Elizabeth II Health Sciences Centre (CA)
- Kantonsspital Winterthur (CH)
- Peking University People's Hospital (CN)
- Dana-Farber Cancer Institute (US)
- Université de Nantes (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hôpital Saint-Louis (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Hôpital Saint-Antoine (FR)
- Unite de Genomique du Myelome, Centre Hospitalier Universitaire Rangueil, Toulouse, France;
- Inserm (FR)
- Celgene (United States) (US)
- Centre Hospitalier Universitaire de Tours (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- ORCID
- Facon, Thierry
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar J.
- Banos, Anne
- Delforge, Michel
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- White, Darrell
- Lu, Jin
- Anderson, Kenneth C.
- Moreau, Philippe
- Attal, Michel
- Perrot, Aurore
- Arnulf, Bertrand
- Qiu, Lugui
- Roussel, Murielle
- Boyle, Eileen
- Manier, Salomon
- Mohty, Mohamad
- Leleu, Xavier
- Chen, Guang
- Benboubker, Lotfi
- Hulin, Cyrille
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-01-18
- Volume
- 131
- Issue
- 3
- Pages
- 301-310
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5774211
- OpenAlex
- W2769593282
- Cited by
- 271
- References
- 23
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 15 · 2023: 31 · 2022: 36 · 2021: 43 · 2020: 48 · 2019: 40 · 2018: 27
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Celgene
- National Cancer Institute (P50CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, transplant-ineligible multiple myeloma, lenalidomide, bortezomib, second-line therapy, survival outcomes, time to next treatment, complete response, secondary malignancies, FIRST trial
- MeSH terms
- Progression-Free Survival, Antineoplastic Agents, Humans, Multiple Myeloma, Survival Analysis, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
